共 50 条
Guidelines on the use of therapeutic apheresis in clinical practice - Evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis
被引:176
|作者:
Szczepiorkowski, Zbigniew M.
Bandarenko, Nicholas
Kim, Haewon C.
Linenberger, Michael L.
Marques, Marisa B.
Sarode, Ravindra
Schwartz, Joseph
Shaz, Beth H.
Weinstein, Robert
Wirk, Ashka
Winters, Jeffrey L.
机构:
[1] Dartmouth Coll, Hitchcock Med Ctr, Dept Pathol, Transfus Med Serv, Lebanon, NH 03756 USA
[2] Univ N Carolina Hosp, Dept Pathol & Lab Med, Chapel Hill, NC USA
[3] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[4] Seattle Canc Care Alliance, Dept Pathol & Lab Med, Seattle, WA USA
[5] Univ Alabama Birmingham, Div Transfus Med, Birmingham, AL 35233 USA
[6] Univ Texas, SW Med Ctr, Dept Pathol, Transfus Med & Coagulat Lab, Dallas, TX 75216 USA
[7] Columbia Univ, Med Ctr, Dept Pathol, Div Lab Med, New York, NY 10027 USA
[8] Emory Univ, Grady Hosp, Dept Pathol & Lab Med, Atlanta, GA 30322 USA
[9] Univ Massachusetts, Med Ctr, Dept Pathol, Div Transfus Med, Worcester, MA 01605 USA
[10] Malachite Management, Vancouver, BC, Canada
[11] Mayo Clin, Div Transfus Med, Rochester, MN USA
关键词:
apheresis;
plasma exchange;
immunoadsorption;
leukocytapheresis;
photopheresis;
categories;
indications;
evidence based;
D O I:
10.1002/jca.20129
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
The American Society for Apheresis (ASFA) Apheresis Applications Committee is charged with a review and categorization of indications for therapeutic apheresis. This elaborate process had been undertaken every 7 years resulting in three prior publications in 1986, 1993, and 2000 of "The ASFA Special Issues." This article is the integral part of the Fourth ASFA Special Issue. The Fourth ASFA Special Issue is significantly modified in comparison to the previous editions. A new concept of a fact sheet has been introduced. The fact sheet succinctly summarizes the evidence for the use of therapeutic apheresis. A detailed description of the fact sheet is provided. The article consists of 53 fact sheets devoted to each disease entity currently categorized by the ASFA. Categories I, II, and III are defined as previously in the Third Special Issue. However, a few new therapeutic apheresis modalities, not yet approved in the United States or are currently in clinical trials, have been assigned category P (pending) by the ASFA Clinical Categories Subcommittee. The diseases assigned to category IV are discussed in a separate article in this issue.
引用
收藏
页码:106 / 175
页数:70
相关论文